Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HK1 | P19367 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892233 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL10411734 | 0.79 | SMN1; SMN2 (0.54) | ALDH1A1MAPK1SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10639171 | 0.79 | PDE10A (0.34) | ALDH1A1MAPK1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL11985884 | 0.79 | LMNA (0.42) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL2091242 | 0.79 | LMNA (0.47) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL1886976 | 0.77 | POLB (0.45) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL30124712 | 0.77 | POLB (0.45) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL26617136 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL26608375 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL20260106 | 0.75 | SMN1; SMN2 (0.41) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-0832067-B1 | PROCESS FOR CONVERTING 2,4-DICHLOROPYRIDINES INTO 2-ARYLOXY-4-CHLOROPYRIDINES | PFIZER (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6316631-B1 | REACTING 2,4-DICHLORO-3,6-DIALKYLPYRIDINE WITH PHENOL DERIVATIVE IN PRESENCE OF BASE AND COPPER CHLORIDE OR COPPER IODIDE OR COPPER BROMIDE TO FORM 2-ARYLOXY-4-CHLOROPYRIDINE COMPOUND, SALT FOMATION | PFIZER INC. | 2001-11-13 | — | — | US | disclosed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6043260-A | Method of treating heart failure | PFIZER INC (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0951906-A1 | Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5962479-A | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0832067-A1 | PROCESS FOR CONVERTING 2,4-DICHLOROPYRIDINES INTO 2-ARYLOXY-4-CHLOROPYRIDINES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1996039388-A1 | PROCESS FOR CONVERTING 2,4-DICHLOROPYRIDINES INTO 2-ARYLOXY-4-CHLOROPYRIDINES | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885MAPK1 458/4885SMN1; SMN2 2967/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885MAPK1 458/4885SMN1; SMN2 2967/4885 |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | ALDH1A1 168/4885MAPK1 316/4885SMN1; SMN2 4482/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | ALDH1A1 3858/4885MAPK1 769/4885SMN1; SMN2 2591/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | ALDH1A1 168/4885MAPK1 316/4885SMN1; SMN2 4482/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885MAPK1 458/4885SMN1; SMN2 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.